EDITORIAL: Antigenic Response to Ct-P13 and Infliximab Originator in Ibd Shows Similar Epitope Recognition-Evidence from Basic Science Supports Safe Switching to Biosimilars. Authors' Reply
AuthID
P-00P-E38
P-00P-E38